StockIQpro
NASDAQ:FLNA

Filana Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Filana Therapeutics, Inc. reported net income of −$91.0M in fiscal 2025. Free cash flow was −$32.8M, and the diluted share count rose 3.6%.Summary generated from Filana Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−82.7%
Debt / equityn/a
Free cash flow−$32.8M
FCF marginn/a
Share count change+3.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−33−80−106−141−95
Net income−32−76−97−24−91
Free cash flow−52−80−82−117−33

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations